Can I Take 5-HTP with Addyi (Flibanserin)? Interaction Guide
Learn whether 5-HTP is safe to take with Addyi (flibanserin), what the serotonin syndrome risk means in practice, and what your prescriber needs to know before you combine them.
30 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

Showing 30 of 30 clinical reviews.
Learn whether 5-HTP is safe to take with Addyi (flibanserin), what the serotonin syndrome risk means in practice, and what your prescriber needs to know before you combine them.
A physician-reviewed guide covering the pharmacokinetic and pharmacodynamic interactions between alpha-lipoic acid and flibanserin (Addyi), including hypoglycemia risk, CYP3A4 considerations, thyroid hormone effects, monitoring protocols, and practical dosing guidance.
A clinician-reviewed guide to the ashwagandha-flibanserin interaction: pharmacokinetics, cortisol and thyroid effects, hypotension risk, dosing strategy, and when to call your prescriber.
Berberine inhibits CYP3A4, the same enzyme that clears flibanserin (Addyi). Learn what the pharmacokinetic data shows, what the FDA warning means for you, and how to talk to your prescriber before combining these two.
A physician-reviewed breakdown of the caffeine-flibanserin interaction: the pharmacokinetics, the hypotension risk, safe caffeine thresholds, and exactly what to do if you are already taking both.
Calcium and flibanserin (Addyi) have no known direct pharmacokinetic interaction. Learn why they are generally safe to take together, how to time your doses, and what to watch for.
A physician-reviewed guide to the CoQ10 and Addyi (flibanserin) interaction, covering pharmacokinetics, pharmacodynamics, blood pressure risks, dosing windows, and monitoring for premenopausal women with HSDD.
A clinician-reviewed guide covering the creatine-flibanserin interaction, how creatine affects serum creatinine, renal monitoring recommendations, and practical advice for women taking Addyi who also use creatine supplements.
A clinical review of the folate-flibanserin interaction: pharmacokinetics, MTHFR relevance, safe dosing windows, and monitoring guidance for women taking Addyi.
A clinical review of the ginseng-flibanserin interaction: pharmacokinetics, pharmacodynamics, glucose effects, CNS risks, and what premenopausal women on Addyi need to know before adding ginseng.
A clinician-reviewed guide to the glutathione, flibanserin interaction: pharmacokinetics, CYP3A4 inhibition risk, dosing windows, monitoring, and when to contact your prescriber.
A clinician-reviewed guide to combining glycine supplements with Addyi (flibanserin), covering pharmacokinetic and pharmacodynamic interactions, dosing windows, monitoring, and safety.
A board-reviewed clinical guide on the hepatotoxicity and CYP3A4 interaction between green tea extract / EGCG and flibanserin (Addyi), with dosing context, monitoring guidance, and what to do if you are already taking both.
A clinician-reviewed guide to the L-theanine and Addyi (flibanserin) interaction: pharmacokinetics, CNS risks, dose timing, and what premenopausal women with HSDD need to know before combining them.
A board-reviewed guide to the lion's mane and flibanserin (Addyi) interaction: mechanisms, safety evidence, monitoring steps, and what to do if you are already taking both.
A clinician-reviewed guide to the magnesium-flibanserin interaction: pharmacokinetics, safety evidence, dosing windows, and monitoring advice for women taking Addyi.
Learn whether melatonin is safe to take with Addyi (flibanserin), including pharmacokinetic and pharmacodynamic considerations, dose-separation strategies, and monitoring recommendations.
A physician-reviewed guide to the NAC and Addyi interaction: pharmacokinetics, CYP3A4 considerations, glutathione pathways, safety monitoring, and clinical guidance for women taking flibanserin for HSDD.
A clinical review of the interaction between omega-3 fatty acids (EPA/DHA) and flibanserin (Addyi), covering pharmacokinetics, antiplatelet effects, CNS overlap, monitoring, and safe co-administration guidance.
Quercetin inhibits CYP3A4 and may raise flibanserin blood levels, increasing sedation and hypotension risk. Learn the mechanism, dose-separation strategies, and when to call your prescriber.
A physician-reviewed guide to the flibanserin and reishi mushroom interaction, covering pharmacokinetics, pharmacodynamics, anticoagulation risk, CNS depression, and safe monitoring steps.
Resveratrol may inhibit CYP3A4, the primary enzyme that metabolizes flibanserin (Addyi). Learn about the interaction mechanism, dose-separation strategies, monitoring needs, and what to do if you already take both.
Rhodiola rosea and Addyi (flibanserin) both affect serotonin pathways. Learn about potential pharmacodynamic interactions, serotonin syndrome risk, dose-separation strategies, and monitoring recommendations.
A clinician-reviewed guide covering the pharmacokinetic and pharmacodynamic interactions between saw palmetto and flibanserin (Addyi), including safety considerations, monitoring guidance, and what to do if you are already taking both.
St. John's Wort is a potent CYP3A4 inducer that drops flibanserin plasma levels by up to 54%, increasing hypotension and CNS depression risk. Learn the mechanism, clinical consequences, and safer alternatives.
A board-reviewed guide to the turmeric, flibanserin interaction: pharmacokinetics, CYP3A4 inhibition, bleeding risk, dosing windows, and what to tell your prescriber.
Evidence-based guide on taking vitamin B12 with Addyi (flibanserin). Covers interaction risk, pharmacokinetic data, dose timing, monitoring, and clinical recommendations.
A clinical review of the vitamin B6 and flibanserin (Addyi) interaction: pharmacokinetics, dose considerations, neuropathy risk, and what your prescriber needs to know before you combine them.
A clinician-reviewed guide to combining vitamin D supplementation with Addyi (flibanserin) for HSDD. Covers pharmacokinetics, interaction evidence, dosing, and monitoring.
Learn whether zinc supplements are safe to take with Addyi (flibanserin), what the pharmacokinetic and pharmacodynamic data show, and how to monitor if you are already taking both.